Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd(University of Cincinnati), Wojciech Jurczak(Jagiellonian University), Susan O’Brien(University of California, Irvine), Árpád Illés(University of Debrecen), Richard R. Furman(Cornell University), Stephan Stilgenbauer(Universität Ulm), Kara Higgins(AstraZeneca (United States)), Wayne Rothbaum, Raquel Izumi, Stéphane Leprêtre(Normandie Université), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Sophia Sohoni(AstraZeneca (United States)), Arnon P. Kater(Amsterdam University Medical Centers), Ahmed Hamdy(Pharmacyclics (United States)), Mustafa Nuri Yenerel(Istanbul University), John F. Seymour(The Royal Melbourne Hospital), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), José A. García‐Marco(Hospital Universitario Puerta de Hierro Majadahonda), Tadeusz Robak(Medical University of Lodz), Paolo Ghia(Vita-Salute San Raffaele University), Javier Pinilla‐Ibarz(Moffitt Cancer Center), Asher Chanan-Khan(Memorial Sloan Kettering Cancer Center), Priti Patel(AstraZeneca (United States)), Neil E. Kay(Mayo Clinic)
Cited by 630
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k